{"id":249876,"date":"2023-06-15T00:00:00","date_gmt":"2023-06-15T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0003-biopharma-alzheimers-disease-epidemiology-mature\/"},"modified":"2026-03-31T10:32:53","modified_gmt":"2026-03-31T10:32:53","slug":"epidcg0003-biopharma-alzheimers-disease-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0003-biopharma-alzheimers-disease-epidemiology-mature-markets\/","title":{"rendered":"Alzheimer&#8217;s Disease &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of Alzheimer\u2019s disease (<abbr title=\"Alzheimer's disease\">AD<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of <abbr title=\"Alzheimer's disease\">AD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and Europe and 10 years for the other countries covered in this report. In addition to forecasting lifetime prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in high-income countries.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"Alzheimer's disease\">AD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"Alzheimer's disease\">AD<\/abbr>, how many in each high-income country are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"Alzheimer's disease\">AD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"multiple sclerosis\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts the following patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of asymptomatic <abbr title=\"Alzheimer's disease\">AD<\/abbr>.<\/li>\n<li>Total prevalent cases of mild cognitive impairment (<abbr title=\"mild cognitive impairment\">MCI<\/abbr>) due to <abbr title=\"Alzheimer's disease\">AD<\/abbr> by symptoms (agitation, depression, hallucinations).<\/li>\n<li>Total prevalent cases of symptomatic <abbr title=\"mild cognitive impairment\">MCI<\/abbr> due to <abbr title=\"Alzheimer's disease\">AD<\/abbr> by diagnosis status.<\/li>\n<li>Total prevalent cases of <abbr title=\"Alzheimer's disease\">AD<\/abbr>.<\/li>\n<li>Total prevalent cases of <abbr title=\"Alzheimer's disease\">AD<\/abbr> by severity (mild, moderate, severe).<\/li>\n<li>Total prevalent cases of <abbr title=\"Alzheimer's disease\">AD<\/abbr> by diagnosis status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"Alzheimer's disease\">AD<\/abbr> by symptom status (agitation, depression, hallucinations).<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"mild cognitive impairment\">MCI<\/abbr> due to <abbr title=\"Alzheimer's disease\">AD<\/abbr> by drug-treatment status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"Alzheimer's disease\">AD<\/abbr> by drug-treatment status.<\/li>\n<li>Diagnosed prevalent cases of mild <abbr title=\"Alzheimer's disease\">AD<\/abbr> by drug-treatment status.<\/li>\n<li>Diagnosed prevalent cases of moderate <abbr title=\"Alzheimer's disease\">AD<\/abbr> by drug-treatment status.<\/li>\n<li>Diagnosed prevalent cases of severe <abbr title=\"Alzheimer's disease\">AD<\/abbr> by drug-treatment status.<\/li>\n<\/ul>\n<p>\u2026 and many more (details available on request).<\/p>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-249876","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249876\/revisions"}],"predecessor-version":[{"id":281499,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249876\/revisions\/281499"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}